comprehensive -WSS

comprehensive

author：leisure time 2025-08-23 05:03:46 - browse：9784

Sorrento Therapeutics — ARIANA DREHSLER/AFP via Getty Images

SAN DIEGO — U.S. legislation that seeks to restrict American biotechs from working with certain Chinese firms and suppliers is for now just that — a proposal, not a law. But the looming bill’s impact was clearly visible at this year’s meeting of the industry’s largest trade group.

A number of biotech companies in attendance at the meeting of the Biotechnology Innovation Organization told STAT they’re actively looking to strike deals with U.S.-based drug manufacturers rather than companies named in the legislation, even though doing so will be more costly. An executive at a U.S.-based contract development and manufacturing organization, or CDMO, who spoke on condition of anonymity, said that “month to month, new business has gone through the roof.”

Meanwhile, some Chinese suppliers not named in the bill are paradoxically drawing increased interest from biotechs — while hearing from some customers worried those manufacturers could be blacklisted in the future.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Duchenne breakthrough therapy leaves behind pioneering families
Next article： FDA drug safety: Singulair case shows systemic surveillance flaws

knowledge

WSS

General Catalyst, Summa Health deal will turn on physician buy

Guidelines to prevent youth baseball injuries need more muscle

Cybersecurity threat forces Lurie Children's to take systems offline

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Biden administration opens offers in Medicare drug price negotiations

Juul spent big to court Black leaders to promote its e

knowledge

comprehensive

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

BioMarin wins approval for gene therapy to treat hemophilia A

Drug repurposing or repositioning? The language matters

Malaria cases in Florida and Texas: Here’s what you need to know

Peter Hotez and the public health issue of online harassment

The cancer drug shortage isn’t new — and neither are the solutions

Drug repurposing or repositioning? The language matters

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Continuity nursing helped my family in our darkest PICU moments

How to save PrEP access — and even expand it

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

hotspot

Affirmative action in medical school literally saved lives

FDA drug safety: Singulair case shows systemic surveillance flaws

Activists slam private health insurers over coverage restrictions

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Even great ERs can’t make up for American health disparities

Jerome Adams on the need for new antivirals for Covid

knowledge

knowledge

knowledge

knowledge